The Lancet Global Health
-
1
[Comment] Inequities in HIV prevention: strategic access and equity in injectable PrEP distribution
-
2
[Comment] The lenacapavir paradox: why a promising prevention tool raises difficult questions about African HIV response priorities
-
3
[Articles] Effects of a peer-support lifestyle intervention on diabetes incidence in India (K-DPP): 9-year follow-up of a cluster-randomised, controlled trial
-
4
[Health Policy] Factors shaping the priority of cancer in global health: a qualitative policy analysis
-
5
[Comment] Nutrition-sensitive social protection saves money and lives
-
6
[Articles] Adaptive intervention strategies for malaria vector control in western Kenya: a cluster, sequential, multiple-assignment, randomised, open-label trial
-
7
[Articles] Effectiveness and cost-effectiveness of a stepped care framework for psychological interventions for reducing common mental health symptoms in Jordan: a single-blind randomised clinical trial
-
8
[Comment] How (not) to organise a panel at a global health conference
-
9
[Articles] Spatial distribution of noma incidence in Nigeria, 1999–2024: a modelling study
-
10
[Correspondence] The hidden dimension of tuberculosis: non-human primate reservoirs and One Health strategies
The Lancet Healthy Longevity
-
1
[Articles] Accelerated deficit accumulation in frailty and associations with adverse outcomes: a longitudinal population data analysis
-
2
[Review] Stroke in older adults: exploring the intersections of comorbidity, disability, and frailty
-
3
[Editorial] Prioritising cancer survivorship care
-
4
[Series] Strengthening health-care pathways for people with Down syndrome
The Lancet HIV
-
1
[Profile] 25 years of the Alliance for Public Health in Ukraine
-
2
[Articles] Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial
-
3
[Review] The vaginal microbiome and HIV acquisition risk
-
4
[Comment] The caveats of short-cycle antiretroviral therapy in adolescents living with HIV
-
5
[Articles] Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
-
6
[Viewpoint] Targeted universalism for long-acting PrEP: an urgent need to avoid risk targeting and build population-level impact
-
7
[Comment] Ending HIV requires research in and with South Africa
-
8
[Feature] Russia's internet blackout affects HIV services
-
9
[Feature] Lenacapavir PrEP roll-out begins in Africa
-
10
[Articles] Trends in incidence of HIV and other sexually transmissible infections among transgender people in Australia: a retrospective 10-year national clinical cohort study
The Lancet Infectious Diseases
-
1
[Personal View] Post-tuberculosis lung disease: a case definition for use in research studies
-
2
[Review] Best practice guidelines for viral hepatitis service delivery in prisons
-
3
[Personal View] Transitioning to people-centred antimicrobial resistance surveillance
-
4
[Grand Round] Management of critical illness in an adolescent caused by highly pathogenic avian influenza A(H5N1) virus infection in British Columbia, Canada
-
5
[Personal View] Time to re-evaluate combination antifungal therapy for invasive aspergillosis and other invasive mycoses
-
6
[Personal View] The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward
-
7
[Articles] Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study
-
8
[Articles] Post-discharge sequelae of Lassa fever survivors in Nigeria: an analysis of the LASCOPE prospective cohort
-
9
[Articles] Evaluating dengue transmission dynamics in an endemic urban setting in Viet Nam: an index-household contact cohort study
-
10
[Articles] Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, randomised controlled trial
The Lancet Neurology
-
1
[Review] The role of lifestyle interventions in symptom management and disease modification in Parkinson's disease
-
2
[Comment] Advances in understanding sudden unexpected death in people with drug-resistant epilepsy
-
3
[Articles] Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPO2MSE): a prospective, multicentre case–control study
The Lancet Microbe
-
1
[Correspondence] Amoebic CNS disease: when terminology obscures biology
-
2
[Personal View] The role of microbial genomics in delivering the UK’s national action plan for confronting antimicrobial resistance 2024–29
-
3
[Correspondence] Understanding the cervicovaginal immune response to Lactobacillus crispatus CTV-05
-
4
[Correspondence] Understanding the cervicovaginal immune response to Lactobacillus crispatus CTV-05
-
5
[Correspondence] Convergence of hypervirulence and multidrug resistance driven by plasmid hybridisation and insertion sequence-mediated chromosomal integration in Klebsiella pneumoniae
-
6
[Correspondence] HIV drug resistance in the era of antiretroviral therapy expansion: the hidden cost of success
-
7
[Comment] Overcoming structural barriers to tuberculosis treatment in Africa through digital technologies
-
8
[Comment] Genetic platforms, bacterial hosts, and ecological contexts enable emergence and restrict dissemination of non-epidemic acquired carbapenemases
-
9
[Personal View] The diagnostic void: how typhoid-by-default drives antimicrobial resistance in Ethiopia
-
10
[Correspondence] Clinically dominant AbST23 iuc3 plasmids are widespread in animal-derived Klebsiella pneumoniae
The Lancet Oncology
-
1
[News] Clinicians have no capacity to deliver on England's national cancer plan, think tank warns
-
2
[News] US drinking water polluted with carcinogenic nitrates
-
3
[News] Air pollution and cancer in Thailand
-
4
[News] US Senate Bill aims to boost cancer trial enrolment and equity
-
5
[Articles] MRI-guided adaptive radiotherapy for high grade glioma (UNITED): a single-centre, single-arm, non-inferiority, phase 2 trial
-
6
[Articles] Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results fro
-
7
[News] Radiation oncologists in the USA fight against policy changes
-
8
[Comment] Reshaping breast cancer radiotherapy after FAST-Forward
-
9
[Articles] Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
-
10
[Articles] Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
The Lancet Planetary Health
-
1
[Comment] Expression of concern: Excess mortality attributed to heat and cold: a health impact assessment study in 854 cities in Europe
-
2
[Corrections] Correction to Lancet Planet Health 2025; 9: e236–44
-
3
[Comment] A call for evidence-based adaptation: mitigating the rising global health burden of extreme heat
-
4
[Corrections] Correction to Lancet Planet Health 2025; 9: 101273
-
5
[Corrections] Correction to Lancet Planet Health 9: 101278
-
6
[Comment] Thank you to The Lancet Planetary Health's statistical and peer reviewers in 2025
-
7
[Newsdesk] Planetary Health Research Digest
-
8
[Corrections] Correction to Lancet Planet Health 2025; 9: e314–25
-
9
[Viewpoint] Global environmental change and the gut–kidney–brain axis: a review and framework of vulnerability and resilience
-
10
[Newsdesk] Planetary Health Research Digest
The Lancet Psychiatry
-
1
[Comment] Assessment of childhood maltreatment in pharmacotherapy trials for schizophrenia
-
2
[Comment] Lived experience research: recognition of dual expertise
-
3
[Comment] Stigmatising language in research and clinical care for body-focused repetitive behaviours
-
4
[Comment] Community-led visions of care for better mental health
-
5
[Comment] The role of male community health workers in global mental health services
-
6
[Comment] US FDA premarket approval of tDCS depression treatment is not yet scientifically justified
-
7
[Comment] Precision language in ADHD research
-
8
[Comment] Marketing of supplements to people with ADHD reinforces stigma
-
9
[Corrections] Correction to Lancet Psychiatry 2026; 13: 441–44
-
10
[Correspondence] The ADOS-2 rapport item: an unexamined assumption